What Iambic Therapeutics does
Iambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing small-molecule therapeutics using an AI-driven discovery and development platform focused on “closed-loop” design–make–test workflows and physics-informed modeling. The company’s platform is organized around multimodal AI models and associated automation that (as described by the company) generate new molecular designs and corresponding biological data on a weekly cadence, then use the resulting data to retrain models and refine target product profiles for candidate selection. Products and platform capabilities are presented as modular model components that can be used both internally to generate wholly owned candidates and externally by partners via technology enablement or discovery collaborations.
In its internal pipeline, Iambic highlights a wholly owned oncology portfolio led by IAM1363 (an oral, selective pan-mutant, brain-penetrant HER2 inhibitor) currently in a multi-center Phase 1/1b clinical study, and additional oncology programs including IAM217 (KIF18A inhibitor; advancing toward clinical stage) and IAM-C1 (CDK2/4 inhibitor). Beyond therapeutics, Iambic markets named AI technologies—most notably Enchant (a multimodal transformer for drug discovery) and NeuralPLexer (protein–ligand structure prediction)—as foundational capabilities that partners can access for target-specific discovery and technology enablement.
Strategically, Iambic’s recent period shows a mix of (1) financing to support clinical and platform expansion, and (2) partnerships with established pharmaceutical companies that combine discovery collaboration with technology/model access. Announced collaborations include Bayer (small molecule discovery using Enchant and NeuralPLexer), Takeda (multi-year technology and discovery collaboration with success-based economics described by the company), Revolution Medicines (technology and research collaboration with NeuralPLexer model access), Jazz Pharmaceuticals (research collaboration and drug supply agreement for IAM1363 combination evaluation), and Lundbeck (strategic research collaboration focused on migraine target discovery).